Company Overview
Advanced Biomed Inc. operates as an investment holding company focused on the research and development of microfluidic biochip technologies designed for precision oncology detection, diagnosis, and treatment within the Taiwan market. The company functions within the healthcare sector, specifically targeting the diagnostics and research industry, which implies a specialization in developing advanced tools for medical analysis rather than manufacturing consumer goods. This entity employs a workforce of 31 individuals to execute its development strategy and maintain its operational facilities. The company holds a market capitalization of $5.71M, while its annual revenue is not available in the provided financial data, and it maintains a small operational footprint with 31 employees. These figures indicate that Advanced Biomed Inc. is a micro-cap entity with limited scale, suggesting that its valuation is driven primarily by its technology pipeline and potential for future expansion rather than established historical revenue streams. The disparity between its minimal employee count and its specific focus on high-tech biochip development highlights a capital-intensive research model where asset value may be concentrated in intellectual property rather than physical infrastructure or large-scale labor forces.
Financial Health
The company reports a net income of $4.05M for the trailing twelve months, yet its revenue for the same period is not available, creating a significant analytical gap that obscures the direct relationship between top-line sales and bottom-line profitability. Additionally, the EBITDA stands at $-2,971,404, revealing that the company is currently operating at an EBITDA loss despite reporting positive net income, which suggests complex tax structures, significant non-operating income, or accounting adjustments that decouple operating cash generation from reported earnings. The free cash flow is reported at $-10,735,010, indicating that the company is burning cash at a substantial rate, which limits its financial flexibility and necessitates reliance on external capital sources or existing cash reserves to fund operations. All three margin metrics—gross margin, operating margin, and profit margin—are listed as 0.0%, which technically indicates either a lack of data availability or a reporting convention where margins are not calculated due to the nature of the investment holding structure or specific accounting treatments. On the liability side, the company holds $2.60M in cash against $714,692 in debt, resulting in a debt-to-equity ratio of 7.54, which signifies a highly leveraged balance sheet relative to its equity base. Despite the high debt-to-equity ratio, the current ratio of 8.56 suggests strong short-term liquidity, as current assets significantly exceed current liabilities, providing a buffer against immediate obligations. Return on Equity is reported at 80.2%, while Return on Assets is -26.9%, a divergence that reveals management is generating substantial returns on shareholder equity, likely amplified by the company's low asset base, even though the overall asset utilization is negative when measured by EBITDA.
Valuation Assessment
Advanced Biomed Inc. exhibits a trailing P/E ratio of 1.19, while the forward P/E is not available, implying that analysts cannot currently project a normalized earnings trajectory due to the absence of forward earnings data. The price-to-book ratio stands at 0.48, indicating that the company's market valuation trades at less than half its book value, which typically suggests the market perceives significant risks or undervaluation relative to the assets recorded on the balance sheet. The price-to-sales ratio is not available, and the EV/EBITDA is -0.89, reflecting the negative earnings multiple associated with the company's current EBITDA loss. The stock has a 52-week high of $80.00 and a 52-week low of $3.61, meaning the current market price sits within a highly compressed range near the bottom of its recent trading history. The beta value is not available, which prevents a direct comparison of the stock's volatility relative to the broader market index, though the wide spread between the high and low suggests inherent price instability. These valuation metrics collectively paint a picture of a speculative asset where traditional multiples are distorted by negative operating performance and a lack of forward-looking earnings estimates.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available in the provided data, preventing a direct calculation of whether earnings are growing faster or slower than revenue. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings back into its research and development operations rather than distributing cash to shareholders. This reinvestment strategy is consistent with the company's status as a growth-stage investment holding company that prioritizes expanding its microfluidic biochip portfolio over providing current income to investors. Consequently, the overall growth and income profile is defined entirely by potential future expansion and capital appreciation, with no current reliance on dividend income or historical growth rates to justify the investment thesis.